- Dysbiosis and structural disruption of the respiratory microbiota in
   COVID-19 patients with severe and fatal outcomes
- 3
- 4 Alejandra Hernández-Terán<sup>1</sup>, Fidencio Mejía-Nepomuceno<sup>1</sup>, María Teresa Herrera<sup>2</sup>, Omar Barreto<sup>3</sup>,
- 5 Emma García<sup>3</sup>, Manuel Castillejos<sup>4</sup>, Celia Boukadida<sup>5</sup>, Margarita Matias-Florentino<sup>5</sup>, Alma Rincón-
- 6 Rubio<sup>5</sup> Santiago Avila-Rios<sup>5</sup>, Mario Mújica-Sánchez<sup>6</sup>, Ricardo Serna-Muñoz<sup>1</sup>, Eduardo Becerril-
- 7 Vargas<sup>6</sup>, Cristobal Guadarrama-Pérez<sup>7</sup>, Víctor Hugo Ahumada-Topete<sup>4</sup>, Sebastián Rodríguez<sup>1</sup>, José
- 8 Arturo Martínez-Orozco<sup>6</sup>, Jorge Salas-Hernández<sup>8</sup>, Rogelio Pérez-Padilla<sup>1</sup>, Joel Armando Vázquez-
- 9 Pére $z^{1*}$ .

#### 10 Affiliations

- <sup>1</sup>Departamento de Investigación en Tabaquismo y EPOC. Instituto Nacional de Enfermedades Respiratorias
   Ismael Cosío Villegas, INER.
- <sup>2</sup>Departamento de Investigación en Microbiología. Instituto Nacional de Enfermedades Respiratorias Ismael
   Cosío Villegas, INER.
- <sup>3</sup>Coordinación de Atención Médica. Instituto Nacional de Enfermedades Respiratorias Ismael Cosío Villegas,
   INER.
- <sup>4</sup>Departamento de Unidad de Epidemiología Hospitalaria e Infectología. Instituto Nacional de Enfermedades
   Respiratorias Ismael Cosío Villegas, INER.
- <sup>5</sup>Centro de Investigación en Enfermedades Infecciosas, CIENI. Instituto Nacional de Enfermedades
   Respiratorias Ismael Cosío Villegas, INER.
- <sup>6</sup>Laboratorio de Microbiología. Instituto Nacional de Enfermedades Respiratorias Ismael Cosío Villegas,
   INER.
- <sup>7</sup>Servicio de Urgencias Médicas. Instituto Nacional de Enfermedades Respiratorias Ismael Cosío Villegas,
   INER.
- <sup>8</sup>Dirección General INER. Instituto Nacional de Enfermedades Respiratorias Ismael Cosío Villegas, INER.
- 26
- 27 \*Corresponding author: Joel Armando Vázquez-Pérez, joevazpe@gmail.com
- 28 Keywords:
- 29 SAR-CoV-2, respiratory microbiota, severity, COVID-19, dysbiosis

## 30 Abstract

COVID-19 outbreak has caused over 3 million deaths worldwide. Understanding disease 31 pathology and the factors that drive severe and fatal clinical outcomes is of special 32 33 relevance. Studying the role of the respiratory microbiota in COVID-19 is particularly 34 important since it's known that the respiratory microbiota interacts with the host immune system, contributing to clinical outcomes in chronic and acute respiratory diseases. Here, 35 we characterized the microbiota in the respiratory tract of patients with mild, severe, or 36 37 fatal COVID-19, and compared with healthy controls and patients with non-COVID-19pneumonia. We comparatively studied the microbial composition, diversity, and microbiota 38 39 structure across study groups and correlated the results with clinical data. We found differences in diversity and abundance of bacteria between groups, higher levels of 40 41 dysbiosis in the respiratory microbiota of COVID-19 patients (regardless of severity level), differences in diversity structure among mild, severe, and fatal COVID-19, and the 42 43 presence of specific bacteria that correlated with clinical variables associated with increased mortality risk. Our data suggest that host-related and environmental factors could 44 45 be affecting the respiratory microbiota before SARS-CoV-2 infection, potentially 46 compromising the immunological response of the host against disease and promoting secondary bacterial infections. For instance, the high levels of dysbiosis coupled with low 47 microbial structural complexity in the respiratory microbiota of COVID-19 patients, 48 49 possibly resulted from antibiotic uptake and comorbidities, could have consequences for the 50 host and microbial community level. Altogether, our findings identify the respiratory 51 microbiota as a potential factor associated with COVID-19 severity.

- 52
- 53
- 54

55

# 57 Introduction

The Coronavirus Disease 2019 (COVID-19) outbreak, declared a pandemic by the World 58 Health Organization on the 11th of March 2020, is caused by the Severe Acute Respiratory 59 Syndrome Coronavirus 2 (SARS-CoV-2). As of May 2021, SARS-CoV-2 has infected 60 more than 150 million people and caused over 3 million deaths worldwide<sup>1</sup>. COVID-19 61 shows a wide spectrum of clinical manifestations ranging from asymptomatic infection and 62 mild respiratory symptoms to severe pneumonia and death, <sup>2,3</sup> which has been related to 63 64 demographic factors and comorbidities. To date, it has been shown that the aberrant 65 immune response against SARS-CoV-2 antigens is critically involved in severe clinical outcomes and other secondary inflammatory conditions that remain after COVID-19<sup>3,4</sup>. 66

Studying the role of the human microbiota in COVID-19 is particularly relevant since it's known that the respiratory microbiota interacts with the host immune system, contributing to clinical outcomes in chronic and acute respiratory diseases <sup>5</sup>. The respiratory microbiota has a central role in shaping pulmonary immunity by boosting innate and adaptive immune responses. Suggesting that host immunity is regulated by interactions with the bacterial communities in the respiratory tract.

Some studies suggest that the interactions between microorganisms and the host immune system are species-specific, denoting that even minor variations in the diversity and composition of the microbiota could have significant consequences on host's health <sup>6</sup>. For COVID-19, severe to fatal clinical outcomes are often associated with the presence of comorbidities that are known to display altered (dysbiotic) microbiota <sup>7</sup> (e.g., diabetes type II, obesity, age, and heart disease). Furthermore, in a wide range of microbiome-associate diseases (MADs), dysbiosis is a common feature that can impact disease progression <sup>8,9</sup>. Nonetheless, few studies characterizing the respiratory microbiota in COVID-19 and the presence of dysbiosis are available to date 10-14.

82 To gain insight into the association between respiratory microbiota and COVID-19 severity; we characterized the microbiota in the respiratory tract of patients with mild, 83 severe, or fatal COVID-19, and compared with healthy controls and patients with non-84 85 COVID-19-pneumonia. We comparatively studied the microbial composition, diversity, 86 and microbiota structure across study groups and correlated the results with clinical data. These analyses let us detect 1) differences in abundance of bacteria between groups, 2) 87 higher levels of dysbiosis in the respiratory microbiota of COVID-19 patients, 3) 88 differences in diversity structure among mild, severe, and fatal COVID-19 microbiota, and 89 90 4) the presence of specific bacteria that correlated with clinical variables associated with 91 increased mortality risk. In summary, our results demonstrate an increasing dysbiosis of the respiratory tract microbiota in COVID-19 patients coupled with a continuous loss of 92 93 microbial complexity structure from mild to fatal COVID-19 that could potentially alter clinical outcomes. Altogether, our findings identify the respiratory microbiota as a potential 94 factor associated with COVID-19 severity. 95

96

97

98

99

# 101 **Results**

### 102 Study participants

Since our sample set consists of upper and lower respiratory tract samples, we kept only 103 upper respiratory samples for the main diversity and statistical analyses. Overall, a total of 104 105 95 samples were analyzed (mild COVID-19 = 37, severe COVID-19 = 27, fatal COVID-19 = 19, healthy control = 7, and non-COVID-19-pneumonia = 5). 106 107 Demographic data, health-related characteristics, and symptomatology are described in 108 Table 1. Overall, 52 patients were male (54.7%) with a median age of 45 years old (IQR: 109 21). Regarding health conditions, 58.2% of the participants presented at least one comorbidity, being DM2 (17%), hypertension (17%), smoking (17%), and obesity (35%) 110 the most widely represented in the cohort. The median days of symptom onset were seven, 111 112 and 52.6% of the individuals received antibiotic treatment before hospitalization. Furthermore, we found important associations between some health/demographic 113 characteristics and severity. For instance, patients with fatal COVID-19 were 114 115 predominantly male (73.6%, p = 0.01), significantly older (median= 58, p = 6.57e-07), with higher BMI (median= 30.4, p = 0.05), and most of them received previous antibiotic 116 treatment (78.9%, p = 0.002) compared with patients with severe and mild COVID-19. 117 Also, a higher number of days after symptoms onset was found in the non-COVID-19-118 119 pneumonia group (median= 10, p = 0.01).

120

# The respiratory microbiota composition differs among severity levels for COVID-19 and controls

From the 95 analyzed samples belonging to the upper respiratory tract, we identified a total

125 of 4514 Amplicon Sequence Variants (ASVs). Regarding the analysis of the relative abundance (Fig. 1A), p\_Firmicutes, p\_Bacteroidetes, and p\_Proteobacteria were the most 126 127 dominant phyla among our severity groups and controls. In general, these phyla are present 128 in all group samples but there are changes in the relative abundance associated with the disease severity. In general, we found p\_Firmicutes, p\_Actinobacteria, p\_TM7, and p\_SR1 129 significantly increased in COVID-19 patients, while p\_Bacteroidetes and p\_Proteobacteria 130 131 were found significantly decreased (Supplementary Table S2). 132 The relative abundance analysis at the genus level revealed genera that significantly differ 133 among COVID-19 patients and controls (Fig. 1B, Supplementary Table S2). In general, we found g\_Veillonella, g\_Staphylococcus, g\_Corynebacterium, g\_Neisseria, 134 135 g\_Actinobacillus, and g\_Selenomonas significantly enriched in the COVID-19 patients but 136 reduced in the healthy controls. In contrast, we found g\_Haemophilus and g\_Alloiococcus enriched in the healthy controls but reduced in the COVID-19 patients. Moreover, there 137 were differences in the abundance of some genera among the severity levels for COVID-138 139 19. For example, g *Streptococcus* and g *Staphylococcus* showed an increasing abundance 140 from mild to fatal COVID-19. In contrast, g Haemophilus and g Actinomyces showed the opposite pattern, where the highest abundance is associated with mild COVID-19 and the 141 142 lowest with the fatal COVID-19. Also, we found g\_Corynebacterium highly abundant only 143 in severe COVID-19, while g Actinobacillus were found highly abundant only in fatal 144 COVID-19.

145 Besides, we compared the most abundant phyla for severe and fatal COVID-19 in the upper

146 and lower respiratory tract (Supplementary Figure S3). In particular, we found differences

147 at phylum and genus level. For instance, for severe COVID-19 patients, we found a higher

abundance of p\_Firmicutes, g\_*Neisseria*, and g\_*Haemophilus* in the lower respiratory tract.

149 In contrast, we found p\_Actinobacteria, p\_Fusobacteria, p\_SR1, and

150 g\_Staphylococcus enriched in the upper respiratory tract. For fatal COVID\_19 patients, we

151 found p\_Proteobacteria, g\_Streptococcus, g\_Neisseria, and g\_Capnocytophaga enriched in

the lower respiratory tract albeit, in the upper respiratory tract, we found p\_TM7, p\_SR1,

153 g\_Corynebacterium, and g\_Staphylococcus. Nonetheless, it is worth mentioning that

154 regardless of the differences found in phyla abundance, we found no differences in beta

155 diversity analyses.

# 156 Alpha diversity

157 Respecting diversity calculated with the Shannon-Wiener index (Fig. 2), we found healthy

158 controls as the most diverse group and the non-COVID-19-pneumonia group (p < 0.05) as

the less diverse. Although among severity groups the differences are not considerable, we

160 did find significant differences among severe and fatal COVID-19 groups (p < 0.05).

161 Beta diversity

162 The beta diversity analyses showed differences in the microbiota composition among

severity levels for COVID-19 and controls (Fig. 3A-B, Supplementary Table S4).

164 Particularly, the PCoA analysis (Fig. 3A) showed differences among severity levels and

165 control groups. Such differences are supported by the PERMANOVA result (F = 2.7, p =

166 0.007). Additionally, the dysbiosis analysis in terms of the Ružička metric allowed us to

167	determine that the microbiota associated with COVID-19 (regardless of severity level)
168	showed significantly higher levels of dysbiosis compared with healthy control
169	(Supplementary Table S4).
170	The LefSe analysis allowed the identification of differentially abundant taxa associated
171	with the compared groups (Fig. 3B). We observed that all the COVID-19 severity groups
172	and the two control groups showed differentially abundant taxa or biomarkers. In particular,
173	for mild COVID-19, we found g_Prevotella melaninogenica and g_P. pallens,
174	g_Veillonella parvula, g_Neisseria subflava, g_Fusobacterium, and g_Actinomyces as
175	highly abundant. For severe COVID-19, we found g_Megasphaera and o_CW040 as the
176	most prevalent. In the case of fatal COVID-19, g_Rothia dentocariosa, g_Streptococcus
177	<i>infantis</i> , and $g_Veillonella$ dispar were the most significant. Moreover, the higher number
178	of differentially abundant taxa were found to be associated with healthy controls (e.g.,
179	g_Streptococcus, g_Flavobacterium, and g_Oribacterium, and f_Veillonellaceae). Finally,
180	for the non-COVID-19-pneumonia group, we found g_Corynebacterium, g_Prevotella
181	nigrescens, g_Capnocytophaga, and f_Enterobacteriaceae as the most abundant.
182	Clinical variables associated with mortality risk correlate with specific microbial
183	groups in the respiratory microbiota

- 184 The Kaplan-Meier survival curves led to the detection of clinical variables that significantly
- 185 correlated with survival probability (Fig. 4-A). For instance, we found that APACHE
- 186 scores above 8 points, levels of Blood Urean Nitrogen (BUN) lower than 40 mg/dl,
- 187 lymphocytes under  $1.25 \times 10^3 / \mu$ l, myoglobin above 110ng/ml, troponin above 3.5ng/ml, and
- urea under 80mg/dl represent high risk by negatively affecting survival probability.

189 The Lefse analysis allowed us to detect bacteria either enriched or depleted in the different

190 risk factor groups for the analyzed variables (Fig. 4-B). We found g\_Neisseria subflava

191 depleted in the high-risk samples for troponin and APACHE. Moreover, g\_Veillonella

192 *dispar* interestingly was found depleted in the low-risk samples for APACHE, BUN,

193 myoglobin, and urea. Nonetheless, we also found some bacterial groups that are constantly

194 enriched in the samples with high-risk for several clinical variables. For instance,

195 g\_Corynebacterium was found enriched in the high-risk samples for lymphocytes count

and urea, while g\_Actinomyces was enriched in BUN and urea. Besides, four ASV's of

197 *Prevotella* genus (g\_*Prevotella melaninogenica*; g\_*Prevotella*; g\_[*Prevotella*];

198 g\_[*Prevotella*]\_s) were found significantly enriched in the high-risk samples for

199 myoglobin, BUN, troponin, and lymphocytes count.

The structure of the respiratory microbiota is different among severity levels for
 COVID-19

202 The network analysis for the microbiota associated with the severity levels for COVID-19

203 revealed differences at a structural level (Fig. 5A-B). The graphic representation of the

204 networks showed a different arrangement for each one and a continuum of loss of

205 complexity across COVID-19 severity groups (from mild to fatal) (Fig. 3A). Particularly,

the network of the microbiota associated with mild COVID-19 was the largest and more

207 connected one (nodes= 148, edges = 4758) compared to severe COVID-19 (nodes=84,

edges=688) and fatal COVID-19 (nodes=74, edges=75). Interestingly, in patients with fatal

209 outcome, the network of the respiratory microbiome was highly disaggregated and poorly

connected with multiple isolated nodes (nodes = 74, edges = 75).

211	The metric calculation of the networks illustrates that the topology associated with each
212	COVID-19 severity level is different (Figure 3B, Supplementary Table S5). For instance,
213	the mild COVID-19 network exhibited the highest values for the average number of
214	neighbors, density, and clustering. In contrast, the severe disease network was characterized
215	by greater centralization, and heterogeneity, while the fatal disease network showed the
216	highest values for diameter, characteristic path length, and connected components.
217	
218	
219	
220	
221	
222	
223	
224	
225	
226	
227	
228	
229	

# 230 **Discussion**

231 COVID-19 pandemic has raised major scientific efforts to identify factors associated with 232 the different disease severity outcomes. Here, we characterized the respiratory microbiota 233 as a potential factor affecting severity outcome for COVID-19. We assessed differences in 234 diversity and structure of the microbial communities associated with a large cohort of 235 patients and linked the results to clinical variables to get insights into the mechanisms by 236 which the microbiota may impact host response against the disease. As well in recent studies investigating COVID-19 etiology<sup>3</sup>, we found that demographic 237 and health-related factors showed strong associations with severity. Male sex, high values 238 for BMI, age above 50 years old, and previous antibiotic treatment were significantly 239 240 associated with fatal COVID-19 patients (Table 1), thus potentially favoring the development of a fatal state of the disease. 241 Likewise in previous work exploring COVID-19 associated respiratory microbiota<sup>14,15</sup>, we 242 found significantly lower microbial diversity in the microbiota of COVID-19 patients than 243 244 in the healthy controls (Fig.1A). This result is relevant since, in general, more diversity is correlated with a better response of the microbial systems against perturbance (e.g., 245 disease). A more diverse microbiota can persist after disease (e.g., by functional 246 redundancy) or recovers to an earlier state (e.g., resilience)<sup>16</sup> having direct consequences 247 on the host's health<sup>8</sup>. 248

Furthermore, we found differences in the abundance of some bacteria among our study groups (Fig. 1A, Supplementary Table S2). In particular, as well as other respiratory diseases <sup>17</sup>, we observed an increased ratio of p Firmicutes/p Bacteroidetes in COVID-19 patients. p\_Firmicutes was detected highly abundant while p\_Bacteroidetes where particular decreased in the microbiota associated to COVID-19 patients. This is of particular interest since, in murine models, it has been proven that p\_Bacteroidetes can down-regulate the
expression of ACE2 <sup>18</sup>. Although the correlation was observed in gut microbiota, the particular low abundance of members of such phylum in severe and fatal patients in this work
opens the question about if this process could also take place in the respiratory tract.

258

Regarding the analysis at the genus level, the most significant differences were found in 259 260 potentially pathogenic bacteria (Fig. 1B, Supplementary Table S2). We identified a gradual 261 increase of g *Streptococcus* from mild to fatal COVID-19. Although g *Streptococcus* is 262 usually a commensal member of the respiratory microbiota, it can become pathogenic in the face of environmental disturbs. In higher abundance, such genus it has been linked to viral 263 acute respiratory infections  $^{19,20}$ . Furthermore, genera such as g Veillonella, 264 g\_Staphylococcus, and g\_Actinomyces also exhibited high abundance in the different sever-265 ity levels for COVID-19. Specifically, g\_Veillonella and g\_Actinomyces have been found 266 as opportunistic pathogens in COVID-19<sup>21</sup>. Moreover, g\_Staphylococcus is one of the 267 most common causal agents of secondary infections in respiratory diseases such as influen-268 za <sup>22</sup>. 269

270

Regarding beta diversity, we found some differences among the analyzed groups. For
instance, we observed in the PCoA analysis that the samples belonging to severe and fatal
COVID-19, as well as to the non-COVID-19-pneumonia group, are more alike in terms of
microbial composition than the healthy controls and the mild COVID-19 patients (Fig. 2A).

Moreover, our dysbiosis analysis let us detect that the microbiota of COVID-19 showed
higher levels of dysbiosis than the healthy control (Supplementary Table S4). Several
MADs exhibit this behavior in which microbiota instability (dysbiosis) is present not by the
dominance of one or a few bacteria but by a higher heterogeneity/stochasticity of microbial
groups <sup>9</sup>.

280 Dysbiosis implies a disruption in the bidirectional interactions between the host immune system and the microbial communities, potentially altering functions provided by these 281 communities and reshaping the whole host-microbiota interaction  $^{8,23}$ . It has been shown 282 that microbiota stability is a hallmark of the health and homeostasis of the host  $^{6,8,20}$ . For 283 instance, some reports suggest that there is a homeostatic mechanism that keeps lung 284 285 epithelium in an interferon prime state with antiviral activity against other respiratory 286 infections such as influenza. This particular antiviral response is stimulated by specific pathogen-associated molecular patterns (PAMPs) that are induced by the microbial 287 communities <sup>24</sup>. In this sense, the modification of microbial communities (e.g., dysbiosis) 288 showed in COVID-19 patients could be modifying the specific PAMPs that stimulate this 289 homeostatic antiviral response, allowing for better conditions for respiratory virus infection, 290 291 encompassing SAR-CoV-2.

A common question when studying MADs is whether dysbiosis enhances disease or is caused by it. For COVID-19, the clinical outcome is highly correlated with comorbidities such as hypertension, diabetes, and obesity <sup>7</sup>, which are often associated with dysbiosis in the gut microbiota <sup>21</sup>. This remark, together with the highly distributed antibiotic uptake in COVID-19 patients (53.6% in our cohort, regardless of severity), merits a reflection on the possibility that most of the patients could be dysbiotic at the time of the disease. In other respiratory diseases such as COPD and asthma, it has been shown that dysbiosis in the
respiratory microbiota can lead to a deregulated immune response, increasing inflammatory
processes <sup>6,8,25</sup>. Considering that aberrant immune responses are determinant in COVID-19
progression, a previous dysbiotic respiratory microbiota could be affecting disease
progression.

303 The LefSe analysis (Fig. 3B) shows a differential abundance of microbial groups. For 304 example, we found that most of the groups associated with the healthy controls belong to 305 the so-called "normal" respiratory microbiota (e.g., g\_Streptococcus, g\_Oribacterium, and f\_Veillonellaceae)<sup>26</sup>. In contrast, when we look at the results of the microbiota associated 306 307 with COVID-19 and non-COVID-19-pneumonia groups, other potentially pathogenic 308 microbial groups appear. In particular, in patients with non-COVID-19-pneumonia we found bacteria associated with nosocomial infections such as g Corynebacterium <sup>27,28</sup>. For 309 mild COVID-19, we found some microbial groups associated with disease or bacteremia 310 like g Prevotella melaninogenica, g V. parvula and g Neisseria subflava<sup>7,28</sup>. For the case 311 of severe COVID-19, we found g\_Megasphaera that has been associated with the risk of 312 ventilator-associated pneumonia (VAP) in other studies characterizing COVID-19 313 microbiota<sup>12</sup>. Additionally, we found g *Rothia dentocariosa* highly abundant in deceased 314 patients. This bacteria has been found as the causal agent of secondary pneumonia in H1N1 315 infection <sup>22</sup> and more recently have been associated with disease progression in previous 316 studies characterizing COVID-19 respiratory microbiota, being proposed as a biomarker for 317 the disease  $^{13,14}$ . 318

From a clinical standpoint, it makes sense that a higher mortality predictor such as
APACHE score correlates with low survival in COVID-19 patients. Other clinical factors

such as BUN or urea have also been used as severity markers in respiratory diseases such as 321 community-acquired pneumonia<sup>29</sup>. Acknowledging that multiple pathophysiological 322 considerations still unexplained in SARS-CoV-2 infection, and the multisystemic 323 involvement that has been observed in COVID-19<sup>30</sup>, biochemical markers of organ 324 325 dysfunction such as lymphopenia, elevated myoglobin, and troponin serum levels as those found in this study, can help predict mortality in these patients <sup>31</sup>. Although the association 326 327 of these factors with specific microbial groups in the respiratory tract has not been previously reported, the findings in this study open the path to further study the relationship 328 between respiratory microbiota and clinical outcomes. The identification of pathogenic 329 bacteria such as g Actinomyces g Prevotella and g Corynebacterium in association with 330 two or more clinical factors further supports the current research line trying to correlate the 331 gut-lung axis with pulmonary disease  $^{32}$ . 332

333 Recent studies, as well as this work, suggest that particularly anaerobic bacteria inhabiting 334 the respiratory tract may be involved in COVID-19 pathogenesis and host immune system. In particular, g *Prevotella* has been found to increase in studies with patients with severe 335 disease and have been co-related to cardiac injury and higher risk mortality <sup>31,33</sup>. In this 336 337 work, we found this specific genus associated with four clinical variables that predict mortality in patients with COVID-19 (Fig. 4A). This finding is of special interest 338 considering previous evidence of g\_*Prevotella* enhancing a Th17 mediated response 339 through IL-8, CCL20, and IL-6 secretion <sup>33,34</sup>; both the Th17 response and its cytokines are 340 currently associated with the host's immune response to SARS-CoV-2<sup>35</sup>. 341

Finally, the co-occurrence arrangement of ecological networks lets us identify structuralpatterns that reflect variations in the biological properties of the microbial communities

associated with COVID-19. For instance, we found that all networks are distinguishable in 344 345 terms of topological metrics such as density, clustering, and heterogeneity. It is worth mentioning that such metrics are potentially related to the stability of the systems likewise 346 to other ecological properties such as resilience and redundancy  $^{36}$ . In particular, we found a 347 348 striking pattern of reduction of structural complexity from mild to fatal COVID-19. The loss of complexity is showed by a reduction in the number of nodes, edges (connections), 349 350 density, and clustering. Passing through from a highly connected and dense network (mild COVID-19) to a highly disaggregated, unconnected network (fatal COVID-19) (Fig. 5AB, 351 352 Supplementary Table S5).

Those structural changes can lead to the generation of hypotheses regarding consequences 353 354 at the microbial community level. For instance, changes in structural patterns could 355 potentially be reflected in alterations in the ecological relationships among microorganisms. A common feature in MADs is that commensal/neutral bacteria can become pathogenic at 356 the face of disease <sup>21</sup>. That is the case of bacteria such as g *Prevotella*, g *Veillonella*, 357 g\_Streptococcus, g\_Actinomyces, or g\_Megasphaera, which have been found as 358 opportunistic pathogens in other studies characterizing COVID-19 microbiota<sup>12,19-21</sup> and 359 360 that were also found in this work (severe and fatal associated microbiota (Fig. 2B)). The shift from neutral to deleterious interactions in specific bacteria could be the result of a loss 361 of interactions that maintain the function and stability of the microbial systems. Which in 362 turn, could cause an exacerbate growth of microbial groups potentially pathogenic, but also 363 364 the depletion of beneficial bacteria, altering the whole environment and possibly compromising functions provided by the microbiota to the host. 365

# 367 **Conclusions**

368 Overall, this work provides insights into the role of the respiratory microbiota in COVID-369 19 disease. Our data suggest that host-related and environmental factors could be affecting 370 the respiratory microbiota before SARS-CoV-2 infection, potentially compromising the 371 immunological response of the host against disease and promoting secondary bacterial 372 infections. For instance, the high levels of dysbiosis coupled with poor microbial structural 373 complexity in the respiratory microbiota of COVID-19 patients, possibly resulted from 374 antibiotic uptake and comorbidities, could have consequences at the host and microbial 375 community level. On the one hand, increased dysbiosis in diseased patients could be modifying the PAMPs that stimulate a homeostatic antiviral response, allowing for better 376 conditions for SAR-CoV-2 replication. Additionally, the loss of structural complexity may 377 378 provoke the appearance of opportunistic pathogens that, through ecological competition, 379 can cause the depletion of beneficial bacteria and promote secondary bacterial infections 380 that worsen the clinical outcome. In summary, the findings of this work contribute to understand the pathology of COVID-19 by identifying the respiratory microbiota as a 381 382 potential factor affecting disease outcome. Further investigations looking for the specific 383 mechanisms by which dysbiotic microbiota in the respiratory tract compromise 384 immunological responses against virus infections are needed.

385

386

#### 388 Methods

#### 389 Ethics statement

The Science, Biosecurity and Bioethics Committee of the Instituto Nacional de 390 391 Enfermedades Respiratorias revised and approved the protocol and the consent procedure given by the participants or their legal guardians (B-0520). Additionally, the Institution 392 requested an informed consent for the recovery, storage, and use of the biological remnant 393 394 to research purposes. Study design 395 396 As part of a surveillance program at the Instituto Nacional de Enfermedades Respiratorias Ismael Cosío Villegas (INER), 115 initial respiratory samples (oropharyngeal swabs, 397 nasopharyngeal swabs, and tracheal aspirates) were collected between March 2020 and 398 October 2020. Additionally, we included seven subjects without respiratory symptoms and 399 400 negative SARS-CoV-2 RT-PCR test (healthy), and five patients with pneumonia that were 401 hospitalized but negative to SARS-CoV-2 (non-COVID-19-pneumonia control group).

- 402 Patients with COVID-19 were classified into three mutually exclusive categories of
- 403 severity: a) mild COVID-19 (patients with moderate symptoms that did not required
- 404 hospitalization), b) severe COVID-19 (patients that required hospitalization and were
- 405 subject to Invasive Mechanical Ventilation (IMV)), and c) fatal COVID-19 (deceased
- 406 patients). Overall, a total of 37 patients with mild disease, 38 with severe disease and, 40
- 407 with fatal outcome were included in the study.

#### 409 DNA extraction and 16S rRNA sequencing

410 Respiratory samples, either nasopharyngeal swabs, oropharyngeal swabs or tracheal

- 411 aspirates, for all 127 patients were collected and centrifugated for 15 min at 4,800 g, and
- the pellet was used for DNA extraction. DNA was extracted using the QIAmp Cador
- 413 Pathogen Mini Kit extraction (Qiagen N.V., Hilden, Germany) according to the
- 414 manufacturer's instructions. V3-V4 16S rRNA region was amplified by PCR using the
- 415 primers reported by Klindworth et al (2013)<sup>37</sup> (for more information see Supplementary
- 416 Material S1). Library preparation was done according to the Illumina 16S metagenomic
- 417 sequencing protocol with few modifications. Briefly, 16S amplicons were purified with the
- 418 DNA clean & concentrator kit (Zymo Research, Irvine Cal., USA). Dual indices and
- 419 Illumina sequencing adapters were attached in a second PCR step using Nextera XT Index
- 420 Kit V2 (Illumina, San Diego Cal., USA). Finally, amplicons were purified, pooled in
- 421 equimolar concentrations, and sequenced in a MiSeq Illumina instrument generating
- 422 paired-end reads of 250bp.

# 423 Sequence data processing

424 Illumina raw sequences were processed with QIIME2 (v.2020.8) <sup>38</sup>. Sequences denoising,

425 quality filtering, and chimera checking were performed with DADA2 <sup>39</sup>. From the original

- number of reads (13,533,440), we kept a total of 9,499,204 with an average of 73,637
- 427 sequences per sample. The Amplicon Sequence Variants (ASVs) were aligned with
- 428 MAFFT <sup>40</sup> and used to construct a phylogeny with fasttree2 <sup>41</sup>. ASVs taxonomy was
- 429 assigned with the Näive Bayes classifier *sklearn*  $^{42}$  using the Greengenes 13.8 database  $^{43}$ .

- 430 All ASVs identified as mitochondria (N=10), and chloroplast (N=32) were removed. Raw
- data were deposited in the NCBI Sequence Read Archive (SRA) (PRNAJ726205).

# 432 Diversity, compositional, and statistical analyses

- 433 Since our sample set contains both upper (Oropharyngeal swabs [OPS], Nasopharyngeal
- 434 swabs [NPS]) and lower (Tracheal aspirates [TA]) respiratory tract samples, and it is
- known that these sites vary in microbial composition, we used only upper respiratory
- 436 samples for the main analyses. After this process we kept a total of 95 samples (mild
- 437 COVID-19 = 37, severe COVID-19 = 27, fatal COVID-19 = 19, healthy control = 7, and
- 438 non-COVID-19-pneumonia = 5). We also characterized TA samples to compare levels of
- 439 severity in the microbiota of the upper and lower respiratory tract.

### 440 *Composition analyses*

- 441 In order to determine if the samples associated with different severity levels and controls
- 442 differed in the most abundant phylum and taxa, we plotted a bar graph by using the median
- 443 and standard error of each taxon in the analyzed groups. Besides, we performed a Kruskal-
- 444 Wallis test to determine if there were any significant differences followed by a paired
- 445 Wilcoxon rank-sum test in the "vegan" R package <sup>44</sup>.

#### 446 Alpha diversity

- We calculated the Shannon-Wiener diversity index with the "microbiome" R package <sup>45</sup>. To
  detect potential differences among groups we conducted a Wilcoxon rank-sum test in the
  "vegan" R package <sup>44</sup>.
- 450 *Beta diversity*

We carried out a Principal Coordinates Analysis (PCoA) with weighted UniFrac distance at 451 ASV level in the "phyloseq" R package <sup>46</sup>. Potential differences in beta diversity were 452 addressed with a Permutational Analysis of Variance (PERMANOVA) with 999 453 permutations performed with the "vegan" R package <sup>44</sup>. Additionally, we tested for 454 dispersion and stochasticity as a proxy of dysbiosis in microbial communities <sup>47</sup>. For this, 455 we calculated the Ružička similarity metric in the "CommEcol" R package <sup>48</sup> and 456 457 performed a Wilcoxon rank-sum test to detect potential statistical differences between healthy controls and diseased groups in their intra-treatment sample similarities. Dysbiosis 458 was assumed when the similarities between the healthy microbiota samples were 459 significantly higher than the similarities between the diseased microbiota samples <sup>9</sup>. 460 Finally, to detect differentially abundant taxa associated with severity levels and controls, 461 we performed a Linear Discriminant Analysis (LDA) with effect size (LefSe) at the ASV 462 level using the web-based tool MicrobiomeAnalyst <sup>49</sup>. Only taxa with a LDA score higher 463 464 than 1.5 and a p-value < 0.01 were used. All diversity and statistical analyses were performed in *R* program  $(v.1.3.1)^{50}$ . 465

# 466 Clinical data analyses

In order to analyze the clinical data associated with our patient's cohort, we transform each
clinical variable into a binomial category according to its data distribution. We used cutpoints based on the 25 and 75 percentiles for each variable. For example, for a given
variable, we classified all samples with values above or equal to the 75 percentile as "1",
and all samples with values under the 75 percentile as "2". Subsequently, we constructed
Kaplan-Meier survival curves in SPSS Statistics (version 21) (Chicago, Illinois, USA) by

using the hospitalization days as time variable, the mortality status (either deceased or
alive) as a dependent variable, and the specific clinical qualitative variables as exposure
variable. Only those curves statistically (*p* < 0.05) and biologically meaningful were</li>
retained for subsequent analyses.
Also, to determine if there were differentially abundant bacteria associated with the several
risk factors for the clinical variables obtained from the Kaplan-Meier curves, we performed

a second LefSe analysis. From this result, only taxa with a LDA score higher than 1.5 and a *p*-value < 0.01 were used.</li>

#### 481 Network structure inference

482 We inferred the network structure for the microbiota associated with the different severity levels. Network calculation was performed in the software CoNet<sup>36</sup> by using read counts 483 summarized at the ASV level. One network was constructed for each severity level 484 485 (samples; mild COVID-19: 37, severe COVID-19: 27, and fatal COVID-19: 19). Only cooccurrences statistically supported by the three tested methods (Pearson, Spearman, and 486 487 Kendall) with a correlation > 0.85 and a *p*-value < 0.01 were established as edges in the 488 graphs. Also, we applied a multi-test correction using the Benjamini-Hochberg procedure. Network visualization was performed in Cytoscape (v. 3.8.2)<sup>51</sup>. 489

To further characterize the structure, we computed metrics of the topology of each network
using the NetworkAnalyzer plug-in in Cytoscape <sup>51</sup> and visualized them with a spider chart
constructed in R program.

494

495

#### 496 **REFERENCES**

- WHO. Weekly epidemiological update on COVID-19-11 May 2021. *11 May* 32 (2021). Available at:
   https://www.who.int/publications/m/item/weekly-epidemiological-update-on-covid-19---11-may-
- 499 2021. (Accessed: 12th May 2021)
- Baloch, S., Baloch, M. A., Zheng, T. & Pei, X. The coronavirus disease 2019 (COVID-19) pandemic.
   *Tohoku J. Exp. Med.* 250, 271–278 (2020).
- 502 3. Sharma, R., Agarwal, M., Gupta, M., Somendra, S. & Saxena, S. K. Clinical Characteristics and
- 503 Differential Clinical Diagnosis of Novel Coronavirus Disease 2019 (COVID-19). in *Coronavirus*
- 504 *Disease 2019 (COVID-19): Epidemiology, Pathogenesis, Diagnosis, and Therapeutics* (ed. Saxena, S.

505 K.) 55–70 (Springer Singapore, 2020). doi:10.1007/978-981-15-4814-7\_6

- 506 4. Yeoh, Y. K. *et al.* Gut microbiota composition reflects disease severity and dysfunctional immune
- 507 responses in patients with COVID-19. *Gut* 1–9 (2021). doi:10.1136/gutjnl-2020-323020
- 5. Man, W. H., De Steenhuijsen Piters, W. A. A. & Bogaert, D. The microbiota of the respiratory tract:
  gatekeeper to respiratory health. *Nat. Rev. Microbiol.* 15, 259–270 (2017).
- 510 6. Budden, K. F. *et al.* Functional effects of the microbiota in chronic respiratory disease. *Lancet Respir.*511 *Med.* 7, 907–920 (2019).
- 512 7. Bao, L. *et al.* Oral Microbiome and SARS-CoV-2: Beware of Lung Co-infection. *Front. Microbiol.*513 11, 1–13 (2020).
- Li, K. J. *et al.* Dysbiosis of lower respiratory tract microbiome are associated with inflammation and
  microbial function variety. *Respir. Res.* 20, 1–16 (2019).
- 516 9. Ma, Z. (Sam). Testing the Anna Karenina Principle in Human Microbiome-Associated Diseases.

- 517 *iScience* **23**, 101007 (2020).
- 518 10. Han, Y., Jia, Z., Shi, J., Wang, W. & He, K. The active lung microbiota landscape of COVID-19
  519 patients. *medRxiv* (2021).
- 520 11. Shen, Z. et al. Genomic diversity of SARS-CoV-2 in COVID-19 patients. J. Infect. Dis. 1–27 (2020).
- Lloréns-Rico, V. *et al.* Mechanical ventilation affects respiratory microbiome of COVI-19 patients
  and its interactions with the host. *medRxiv* (2021).
- Marotz, C. *et al.* Microbial context predicts SARS-CoV-2 prevalence in patients and the hospital built
  environment. *medRxiv* (2020). doi:10.1101/2020.11.19.20234229
- 525 14. Xu, R. *et al.* Temporal dynamics of human respiratory and gut microbiomes during the course of
  526 COVID-19 in adults. *medRxiv* 6-
- 527 15. Zhang, H. *et al.* Metatranscriptomic characterization of COVID-19 identified a host transcriptional
  528 classifier associated with immnune signaling. *Clin. Infect. Dis.* (2020).
- 529 16. Allison, S. D. & Martiny, J. B. H. Resistance, resilience, and redundancy in microbial communities.
  530 *Light Evol.* 2, 149–166 (2009).
- 531 17. Wang, B., Yao, M., Lv, L., Ling, Z. & Li, L. The Human Microbiota in Health and Disease.
  532 *Engineering* 3, 71–82 (2017).
- 533 18. Geva-Zatorsky, N. *et al.* Mining the human gut microbiota for immunomodulatory organisms. *Cell*534 168, 928–943 (2017).
- Teo, S. M. *et al.* The infant nasopharyngeal microbiome impacts severity of lower respiratory
  infection and risk of asthma development. *Cell Host Microbe* 17, 704–715 (2015).
- 537 20. Lynch, S. V. The lung microbiome and airway disease. Ann. Am. Thorac. Soc. 13, S462–S465 (2016).
- 538 21. Ferreira, C., Viana, S. D. & Reis, F. Is gut microbiota dysbiosis a predictor of increased susceptibility
- 539 to poor outcome of COVID-19 patients? An update. *Microorganisms* 9, 1–12 (2021).

540	22.	Prakash, R., Sangeetha, S., Lakshminarayana, S. A. & Sunil Kumar, D. C. Secondary Pneumonia due
541		to Rothia mucilaginosa in H1N1 patient. J. Int. Med. Dent. 3, 58-60 (2016).
542	23.	Kumar, P. & Chander, B. COVID 19 mortality: Probable role of microbiome to explain disparity.
543		Med. Hypotheses 144, 110209 (2020).
544	24.	Bradley, K. C. et al. Microbiota-Driven Tonic Interferon Signals in Lung Stromal Cells Protect from
545		Influenza Virus Infection. Cell Rep. 28, 245–256.e4 (2019).
546	25.	Khatiwada, S. & Subedi, A. Lung microbiome and coronavirus disease 2019 (COVID-19): Possible
547		link and implications. Hum. Microbiome J. 17, 100073 (2020).
548	26.	Huffnagle, G. B., Dickson, R. P. & Luckacs, N. W. The respiratory tract microbiome and lung
549		inflammation: a two-way street. Mucosal Immnunol. 10, 299–306 (2017).
550	27.	Renom, F. et al. Respiratory infection by Corynebacterium striatum: Epidemiological and clinical
551		determinants. New Microbes New Infect. 2, 106–114 (2014).
552	28.	Zimmermann, A. et al. Atopobium and Fusobacterium as novel candidates for sarcoidosis-associated
553		microbiota. Eur. Respir. J. 50, 1-10 (2017).
554	29.	Lim, W. S. et al. British Thoracic Society guidelines for the management of community acquired
555		pneumonia in adults: Update 2009. Thorax 64, (2009).
556	30.	Bohn, M. K. et al. Pathophysiology of COVID-19: Mechanisms underlying disease severity and
557		progression. <i>Physiology</i> <b>35</b> , 288–301 (2020).
558	31.	Zheng, Y. Y., Ma, Y. T., Zhang, J. Y. & Xie, X. COVID-19 and the cardiovascular system. Nat. Rev.
559		<i>Cardiol.</i> <b>17,</b> 259–260 (2020).
560	32.	Fromentin, M., Ricard, J. D. & Roux, D. Respiratory microbiome in mechanically ventilated patients:
561		a narrative review. Intensive Care Med. 47, 292–306 (2021).

562 33. Chakraborty, S. Metagenome of SARS-Cov2 patients in Shenzhen with travel to Wuhan shows a

563		wide range of species - Lautropia, Cutibacterium, Haemophilus being most abundant - and
564		Campylobacter explaining diarrhea. OSF Prepr. 6-7 (2020). doi:10.31219/osf.io/jegwq
565	34.	Larsen, J. M. The immune response to Prevotella bacteria in chronic inflammatory disease.
566		Immunology <b>151,</b> 363–374 (2017).
567	35.	De Biasi, S. et al. Marked T cell activation, senescence, exhaustion and skewing towards TH17 in
568		patients with COVID-19 pneumonia. Nat. Commun. 11, 1-17 (2020).
569	36.	Faust, K. & Raes, J. CoNet app: Inference of biological association networks using Cytoscape.
570		<i>F1000Research</i> <b>5</b> , 1–14 (2016).
571	37.	Klindworth, A. et al. Evaluation of general 16S ribosomal RNA gene PCR primers for classical and
572		next-generation sequencing-based diversity studies. Nucleic Acids Res. 41, 1–11 (2013).
573	38.	Bolyen, E. et al. Reproducible, interactive, scalable and extensible microbiome data science using
574		QIIME 2. Nat. Biotechnol. 37, 852–857 (2019).
575	39.	Callahan, B. J. et al. DADA2: High resolution sample inference from Illumina amplicon data. Nat.
576		<i>Methods</i> <b>13,</b> 4–5 (2016).
577	40.	Katoh, K., Misawa, K., Kuma, K. I. & Miyata, T. MAFFT: A novel method for rapid multiple
578		sequence alignment based on fast Fourier transform. Nucleic Acids Res. 30, 3059–3066 (2002).
579	41.	Price, M. N., Dehal, P. S. & Arkin, A. P. FastTree 2 - Approximately maximum-likelihood trees for
580		large alignments. PLoS One 5, (2010).
581	42.	Bokulich, N. A. et al. Optimizing taxonomic classification of marker-gene amplicon sequences with
582		QIIME 2's q2-feature-classifier plugin. <i>Microbiome</i> 6, 1–17 (2018).
583	43.	McDonald, D. et al. An improved Greengenes taxonomy with explicit ranks for ecological and
584		evolutionary analyses of bacteria and archaea. ISME J. 6, 610–618 (2012).
585	44.	Oksanen, J. et al. Community ecology package. (2013).

- 586 45. Lahti, L., Shetty, S. & et al. Tools for microbiome analysis in R. (2017).
- 587 46. McMurdie, P. J. & Holmes, S. Phyloseq: An R Package for Reproducible Interactive Analysis and
  588 Graphics of Microbiome Census Data. *PLoS One* 8, (2013).
- 589 47. Ning, D., Deng, Y., Tiedje, J. M. & Zhou, J. A general framework for quantitatively assessing
- 590 ecological stochasticity. *Proc. Natl. Acad. Sci. U. S. A.* **116**, 16892–16898 (2019).
- 591 48. Melo, A. S. CommEcol: community ecology analyses. 1 (2016).
- 592 49. Dhariwal, A. *et al.* MicrobiomeAnalyst: A web-based tool for comprehensive statistical, visual and
  593 meta-analysis of microbiome data. *Nucleic Acids Res.* 45, W180–W188 (2017).
- 594 50. Team, R. C. R: A language and environment for statistical computing. (2020).
- 595 51. Shannon, P. *et al.* Cytoscape: A Software Environment for Integrated Models. *Genome Res.* 2498–
  596 2504 (2003). doi:10.1101/gr.1239303.metabolite

597

#### 598 Acknowledgments

We are thankful for the excellent clinical care of all physician and nurses at INER attendingCOVID 19 patients.

### 601 Author contributions

- 602 AHT, JSH, RPP, and JAVP conceived and designed the project. OB, EG, EBV, CGP, and
- 603 VHAT collected the clinical data and constructed the database. AHT, FMN, CB, MM,
- 604 ARR, and JVP performed the experimental laboratory procedures. AHT and MC
- 605 performed the bioinformatics and statistical analyses. MTH, RS, SR, and JAVP
- 606 performed the interpretation of clinical data. AHT, FMN, MTH, SAR, RS, SR, RPP, and

- 607 JAVP wrote the manuscript. JAVP supervised the project and led the team. All authors
- 608 discussed the results and commented on the manuscript.

### 609

## 610 Competing Interests Statement

611 The authors declare that they have no competing interests.

# 612 Funding

- 613 This work was financially supported by Consejo Nacional de Ciencia y Tecnología
- 614 (CONACYT-FORDECYT 2020, grant "Caracterización de la diversidad viral y
- 615 bacteriana" to JAVP)

# 616

# 617 Data availability

- The sequencing reads generated during the present study are available in the NCBI
- 619 Sequence Read Archive (SRA) accession PRNAJ726205.

# 620 Figure legends

- 621 Table 1. Demographic data of the cohort. Only upper respiratory samples (OPS and NPS) are
- 622 included in the information. Abbreviations: BMI= body mass index, DM2= Diabetes Mellitus Type
- 623 2. \*Respiratory diseases: either asthma, COPD, or ILD. P values denote statistical significant
- 624 differences given by Wilcoxon rank-sum test (\* < 0.05, \*\* < 0.005, \*\*\* < 0.0005).

# Figure 1. Main composition at phylum and genus level among severity levels for COVID-19

- and controls. A: median abundance of most abundant phyla in the analyzed groups. B: median
- 627 abundance of most abundant genera in the analyzed groups. Asterisks denote global statistical
- 628 differences given by Kruskal-Wallis test (p-values: \* < 0.05, \*\* < 0.005, \*\*\* < 0.0005).

- 629 Figure 2. Alpha diversity of the respiratory microbiota among severity levels for COVID-19
- 630 and controls. Boxplot of the Shannon-Wiener index value for all analyzed groups. Asterisks denote
- 631 statistical significant differences given by Wilcoxon rank-sum test (\*p < 0.05).

#### 632 Figure 3. Beta diversity of the respiratory microbiota among severity levels for COVID-19

and controls. A: PCoA with weighted Unifrac distance and PERMANOVA result that test

634 differences in the community arrange among groups. Each ellipse represents an analyzed group

635 specified in the legend. **B:** Differentially abundant taxa obtained through LefSe analysis for each

group. Only features with a LDA score higher than 1.5 and a p < 0.01 were included. ASV:

637 Amplicon Sequence Variant.

#### 638 Figure 4. Correlation among clinical variables affecting survival probability and bacteria in

639 the respiratory microbiota. A: Kaplan-Meier curves for the clinical variables with a statistical

significant difference in survival probability. Variables were classified into two categories

641 specified in the legend "factor". All curves were constructed with hospitalization days and outcome

642 (either deceased or alive). **B:** Bacteria that are significantly depleted or enriched in samples with the

643 different risk factors for the clinical variables obtained trough Kaplan-Meier curves. Risk factor

644 (either high or low) corresponds to the result of the survival curves (panel A). ASV: Amplicon

- 645 Sequence Variant. APACHE: Acute Physiology and Chronic Health Evaluation, BUN: Blood Urea
- 646 Nitrogen.

#### 647 Figure 5. Network structure of the respiratory microbiota among severity levels for COVID-

648 19. A: Co-occurrence/exclusion networks for mild, severe and fatal COVID-19. Each node

represents a microbial group at ASV level and each edge an interaction (either co-occurrence or co-

650 exclusion). Colors denote phylum identity. Number of samples used to construct the network (N),

number of nodes and number of edges are reported in the figure. **B:** Spider chart of the topological

652 metrics associated to each network.

653

654

655

# **Table 1. Demographic data of the cohort**

	All (N= 95)	Healthy control (N=7)	COVID-19 Mild (N=37)	COVID-19 Severe (N=27)	COVID-19 Fatal (N=19)	Non-COVID-19- pneumonia (N=5)	<i>p</i> value
Age (years), median (IQR)	45 (21)	35 (18)	37 (18)	47(21)	58(16.5)	49(13)	6.75e-07 ***
Gender							
Female, n (%)	43 (45.2%)	5 (71.4%)	18 (48.6%)	12 (44%)	5 (26.3%)	3 (60%)	0.016 *
Male, n (%)	52 (54.7%)	2 (28.5%)	19 (51.3%)	15 (55.5%)	14 (73.6%)	2 (40%)	
Smoking, n (%)	15 (17%)	0	0	8 (29.6%)	7 (36.8%)	0	ns
NA	8	1	4	0	1	2	
BMI (kg/m2), median (IQR)	27.6(6.9)	26.2(2.6)	27.34(7.9)	28.9(4.6)	30.4 (9.8)	24.9(2.3)	0.05*
Obesity							
Not obese, n(%)	48 (50.5%)	5 (71.4%)	16 (43.2%)	16 (59.2%)	8 (42.1%)	3 (60%)	ns
Class I, n (%)	16 (61.5%)	0	9 (81.8%)	7 (77.7%)	2 (25%)	0	
Class II, n(%)	7 (29.9%)	0	1(9%)	2 (22%)	4 (50%)	0	
Class III, n(%)	3 (11.5%)	0	1(9%)	0	2 (25%)	0	
NA	21	2	12	2	3	2	
Comorbidities							
DM2, n (%)	15 (17%)	0	3 (8%)	7 (70.3%)	5 (26.3%)	0	ns
Hypertension, n (%)	15 (17%)	0	3 (8%)	4 (14.8%)	8 (42.1%)	0	ns
Respiratory disease*, n (%)	4 (4.5%)	0	3 (8%)	1 (3.7%)	1 (5.2%)	0	ns
NA	36	2	17	1	8	8	
Days after symptoms onset, n (IQR)	7 (6)	NA	5 (5)	6.5 (4.7)	5 (5)	10 (3)	0.01*
Antibiotic treatment, n (%)	50 (52.6%)	1 (14.2%)	11 (29.7%)	21 (77.7%)	15 (78.9%)	2 (40%)	0.002**
Symptoms							
Cough, n (%)	50(52%)	2 (28.5%)	11 (29.7%)	20 (74%)	15 (78.9%)	2 (40%)	ns
Fever, n (%)	48 (50.5%)	2 (28.5%)	10(27%)	19 (70.3%)	15 (78.9%)	2 (40%)	ns
Dyspnea, n (%)	42 (44%)	0	4 (10.8%)	18 (66.6%)	17 (89%)	3 (60%)	ns
Headache, n (%)	40 (42%)	1 (14.2%)	15 (40.5%)	13 (48%)	11 (57.8%)	0	0.001**
Myalgia, n (%)	38 (40%)	2 (28.5%)	12 (32.4%)	13 (48%)	10 (52.6%)	1 (20%)	0.003**
Arthralgia, n (%)	36 (37.8%)	2 (28.5%)	10(27%)	13 (48%)	10 (52.6%)	1 (20%)	0.04*
Fatigue, n (%)	20 (21%)	0	3 (8%)	8 (29.6%)	9 (47%)	0	ns
Rhinorrhea, n (%)	26 (27.3%)	1 (14.2%)	6 (16%)	12 (44%)	6 (31.5%)	1 (20%)	ns
Chest pain, n (%)	13 (13.6%)	0	5 (13%)	4 (14.8%)	4 (21%)	0	ns
Diarrhea, n (%)	16 (16.8%)	0	4 (10.8%)	8 (29.6%)	4 (21%)	0	ns
Cyanosis, n (%)	7 (7.3%)	0	0	3(11%)	4 (21%)	0	ns
Vomiting, n (%)	5 (5.2%)	0	1 (2.7%)	3 (11%)	1 (5.2%)	0	ns
NA	105	0	70	12	0	23	









